Tests higher dulaglutide doses in children with type 2 diabetes
Tests two dulaglutide doses in children aged 10 to 17 with type 2 diabetes.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Albuquerque, Atlanta, Baltimore, Boise, Buffalo, Chapel Hill, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Dallas, Denver, Greenville, Houston, Hyde Park, Indianapolis, Iowa City, Jackson, Jacksonville, Little Rock, Los Angeles, Louisville, Miami, Milwaukee, New Haven, Oklahoma City, Orlando, Philadelphia, Salt Lake City, San Francisco, Seattle, Syracuse, Tamarac, Tampa, Tucson, and Washington D.C., United StatesSee the 41 sitesAlso in 2 other countries, 10 sites
- Trial code
- Registry title
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 55 people, planned
- Started
- 10 Jan 2025
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Dulaglutide
- Record updated
- 7 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 10 to 17 with type 2 diabetes who weigh at least 50 kg (110 lb) and have a high body mass index. They would take dulaglutide.
- Age
- 10 to 17 years
- Sex
- Boys and girls can both join.
- Disease stage
- Type 2 diabetes treated with diet, exercise and metformin and/or basal insulin. Body mass index above the 85th percentile.
- Earlier treatment
- The metformin and/or basal insulin dose must have been stable for at least 8 weeks before screening.
Main reasons for not taking part
- Type 1 diabetes
- Other glucose-lowering medicines (besides metformin, basal insulin or dulaglutide) in the 8 weeks before screening
- Diabetic ketoacidosis or hyperosmolar syndrome after the type 2 diabetes diagnosis
- Severe low blood sugar or unawareness of low blood sugar in the last 6 months
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening
- Have a body weight ≥50 kilograms (kg) and Body Mass Index (BMI) of >85th percentile
Who cannot take part
- Have prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease
- Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening
- Have Type 1 diabetes
- After the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
- Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
- Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or dulaglutide within 8 weeks prior to screening
- Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness within the last 6 months
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 17 years old?
Where in United States
Also in 2 other countries, 10 sites
- University of New Mexico HospitalAlbuquerque, United StatesContact: Michelle Hutchison (principal investigator)Taking people
- Children's Healthcare of Atlanta Center for Advanced PediatricsAtlanta, United StatesContact: Daniel Hsia (principal investigator)Taking people
- Johns Hopkins University School Of MedicineBaltimore, United StatesContact: Risa Wolf (principal investigator)Taking people
- St. Luke's Children's Endocrinology and DiabetesBoise, United StatesContact: Daniel Flynn (principal investigator)Taking people
- WBMD PediatricsBuffalo, United StatesContact: Kathleen Bethin (principal investigator)Taking people
- UNC Children's HospitalChapel Hill, United StatesContact: Nina Jain (principal investigator)Taking people
- University of Illinois at ChicagoChicago, United StatesContact: Roxana Aguirre Castaneda (principal investigator)Taking people
- Childrens Hospital Medical CenterCincinnati, United StatesContact: Ryan Brady (principal investigator)Taking people
- Cleveland Clinic Childrens Outpatient CenterCleveland, United StatesContact: Roy Kim (principal investigator)Taking people
- Prisma Health Pediatric EndocrinologyColumbia, United StatesContact: Alison Lunsford (principal investigator)Taking people
- Centricity Research Columbus EndocrinologyColumbus, United StatesContact: Steven Leichter (principal investigator)Taking people
- Research Institute Of DallasDallas, United StatesContact: Heidi Shea (principal investigator)Taking people
- Children's Hospital of ColoradoDenver, United StatesContact: Melanie Cree (principal investigator)Not yet recruiting
- Prisma Health MidlandsGreenville, United StatesContact: Elaine Apperson (principal investigator)Taking people
- Texas Childrens HospitalHouston, United StatesContact: Siripoom McKay (principal investigator)Taking people
- UT Health HoustonHouston, United StatesContact: Anvi Shah (principal investigator)Taking people
- Cohen Children's Medical Center Division of Pediatric EndocrinologyHyde Park, United StatesContact: Benjamin Nwosu (principal investigator)Taking people
- Center for Diabetes and Metabolic Diseases Indiana UniversityIndianapolis, United StatesContact: Tamara Hannon (principal investigator)Taking people
- University of Iowa Stead Family Children's HospitalsIowa City, United StatesContact: Michael Tansey (principal investigator)Taking people
- University of Mississippi Medical CenterJackson, United StatesContact: Nazmin Dixit (principal investigator)Taking people
- Nemours Children's HealthJacksonville, United StatesContact: Camila Pereira-Eshraghi (principal investigator)Taking people
- Arkansas Childrens HospitalLittle Rock, United StatesContact: Jon Oden (principal investigator)Taking people
- Division of Endocrinology, Diabetes, and MetabolismLos Angeles, United StatesContact: Lily Chao (principal investigator)Taking people
- UCLA Mattel Children's HospitalLos Angeles, United StatesContact: Vibha Singhal (principal investigator)Taking people
- Norton Children's EndocrinologyLouisville, United StatesContact: Sara Watson (principal investigator)Taking people
- D&H National Research Centers, IncMiami, United StatesContact: Yanetsi Flores Landa (principal investigator)Taking people
- Children's Wisconsin - Milwaukee CampusMilwaukee, United StatesContact: Susanne Cabrera (principal investigator)Taking people
- Yale Diabetes ResearchNew Haven, United StatesContact: Michelle Van Name (principal investigator)Taking people
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Jeanie Tryggestad (principal investigator)Taking people
- AdventHealth OrlandoOrlando, United StatesContact: Konda Reddy (principal investigator)Taking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Steven Willi (principal investigator)Taking people
- St Christophers Hospital For ChildrenPhiladelphia, United StatesContact: Elizabeth Suarez (principal investigator)Taking people
- University of UtahSalt Lake City, United StatesContact: Jacqueline Chan (principal investigator)Taking people
- University of California San FranciscoSan Francisco, United StatesContact: Shylaja Sirinivasan (principal investigator)Taking people
- Seattle Children's HospitalSeattle, United StatesContact: Petter Bjornstand (principal investigator)Taking people
- SUNY Upstate Medical UniversitySyracuse, United StatesContact: David Hansen (principal investigator)Taking people
- D&H Tamarac Research Center, LLCTamarac, United StatesContact: Helena Gaviria (principal investigator)Taking people
- University of South FloridaTampa, United StatesContact: Henry Rodriguez (principal investigator)Taking people
- University of ArizonaTucson, United StatesContact: Sunil Sinha (principal investigator)Taking people
- Children's National Medical CenterWashington D.C., United StatesContact: Shideh Majidi (principal investigator)Taking people
- Emerson Clinical Research InstituteWashington D.C., United StatesContact: Julia Pineda (principal investigator)Taking people
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
The group in the trial
- DulaglutideTreatment being tested
Participants will receive dulaglutide subcutaneously (SC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
- Plain-language title
- Tests higher dulaglutide doses in children with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06739122, who can take part
- Record updated
- 7 August 2026